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and Sarcomere Myofilament Gene Mutations
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Michael J. Ackerman, MD, PHD,† Barbara Sotgia, MD,* J. Martijn Bos, MD, PHD,†
Stefano Nistri, MD,* Aurelio Sgalambro, MD,* Camilla Grifoni, MD,* Francesca Torricelli, BSC,*
Paolo G. Camici, MD,‡ Franco Cecchi, MD*
Florence and Milan, Italy; and Rochester, Minnesota
Objectives The purpose of this study was to assess myocardial blood flow (MBF) using positron emission tomography in patients
with hypertrophic cardiomyopathy (HCM) according to genetic status.
Background Coronary microvascular dysfunction is an important feature of HCM, associated with ventricular remodeling and heart
failure. We recently demonstrated the increased prevalence of systolic dysfunction in patients with HCM with sarco-
mere myofilament gene mutations and postulated an association between genetic status and coronary microvascular
dysfunction.
Methods Maximum MBF (intravenous dipyridamole, 0.56 mg/kg; Dip-MBF) was measured using 13N-labeled ammonia in
61 patients with HCM (age 38  14 years), genotyped by automatic DNA sequencing of 8 myofilament-encoding
genes (myosin-binding protein C, beta-myosin heavy chain, regulatory and essential light chains, troponin T, troponin I,
troponin C, alpha-tropomyosin, and alpha-actin). In 35 patients, cardiac magnetic resonance imaging was performed.
Results Fifty-three mutations were identified in 42 of the 61 patients (genotype positive; 69%). Despite similar clinical pro-
files, genotype-positive patients with HCM showed substantially lower Dip-MBF compared with that of genotype-
negative patients (1.7  0.6 ml/min/g vs. 2.4  1.2 ml/min/g; p  0.02). A Dip-MBF 1.5 ml/min/g had 81% posi-
tive predictive value for genotype-positive status and implied a 3.5-fold independent increase in likelihood of carrying
myofilament gene mutations (hazard ratio: 3.52; 95% confidence interval: 1.05 to 11.7; p  0.04). At cardiac mag-
netic resonance imaging, the prevalence of late gadolinium enhancement was greater in genotype-positive patients
(22 of 23 [96%] compared with 8 of 12 [67%] genotype-negative patients; p  0.038).
Conclusions Patients with HCM with sarcomere myofilament mutations are characterized by more severe impairment of microvas-
cular function and increased prevalence of myocardial fibrosis, compared with genotype-negative individuals. These
findings suggest a direct link between sarcomere gene mutations and adverse remodeling of the microcirculation in
HCM, accounting for the increased long-term prevalence of ventricular dysfunction and heart failure in genotype-
positive patients. (J Am Coll Cardiol 2011;58:839–48) © 2011 by the American College of Cardiology Foundation
Published by Elsevier Inc. doi:10.1016/j.jacc.2011.05.018W
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eCoronary microvascular dysfunction (CMD) is an impor-
tant primary feature of hypertrophic cardiomyopathy
(HCM), contributing to myocardial ischemia, left ventric-
ular (LV) remodeling, and adverse outcomes (1– 8).
hether the genetic substrate of HCM might influence
emodeling of the coronary microcirculation, and thus
mpact the severity of CMD, remains to be determined (9).
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ent gene mutations have a higher prevalence of systolic
ysfunction and progression to the end-stage phase, com-
ared with those with a negative genetic test (10). Of note,
ach of these clinical abnormalities is subtended by severe
MD in patients with HCM (4,6,11), a feature often
vident many years before clinical or echocardiographic
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(4,5). We therefore hypothesized
that CMD might be more fre-
quent and severe in HCM asso-
ciated with proven sarcomere
gene mutations, potentially ac-
counting for differential out-
comes based on genetic status
(2). To address this issue, we
used positron emission tomogra-
phy (PET) to assess CMD in a
cohort of patients who received
comprehensive genetic testing
for the principal HCM suscepti-
bility genes. In a subset of pa-
tients, we also assessed the rela-
tionship between mutational
status and prevalence of late gad-
olinium enhancement (LGE) as-
sessed by cardiac magnetic reso-
nance imaging (MRI).
Methods
Patients with HCM. The study cohort included 61 unre-
ated patients (age 38  14 years; 72% male) undergoing
ET for evaluation of symptoms such as dyspnea (n  24),
ngina (n  12), or risk stratification (n  25). The
diagnosis of HCM was based on 2-dimensional echocar-
diographic evidence of a hypertrophied LV (maximal wall
thickness 15 mm) in the absence of any other cardiac or
systemic cause of LV hypertrophy (1). Patients were en-
rolled from a large (n  1,000) HCM population followed
at our institution, among the 325 patients who completed
an 8-gene mutational panel by December 2009. Children
age 15 years and potentially child-bearing female patients
were excluded. Although representing approximately 25%
of potentially eligible patients, the study group is considered
representative of the whole HCM cohort, based on age, sex,
New York Heart Association (NYHA) functional class,
prevalence of sarcomere gene mutations, and clinical status
(10,12) (Table 1).
For all patients, informed consent was obtained, and the
study protocol was approved by the local ethics committee.
In all patients, epicardial coronary artery disease was ex-
cluded at the time of enrollment by maximal, symptom-
limited cycloergometer echocardiography (performed rou-
tinely in our patients with HCM), followed by coronary
angiography in patients with a positive or dubious test
result. Patients with angina on effort were also studied
invasively. Overall, coronary angiography was performed in
16 of the 61 study patients (26%) and was negative in each
case. No evidence of regional perfusion defects on PET
were observed, and the microvascular abnormalities were
Abbreviations
and Acronyms
CMD  coronary
microvascular dysfunction
Dip-MBF  myocardial
blood flow following
dipyridamole infusion
GLA  galactosidase
HCM  hypertrophic
cardiomyopathy
LGE  late gadolinium
enhancement
LV  left ventricle/
ventricular
MYBPC3  myosin-binding
protein C
MYH7  beta-myosin heavy
chain
PET  positron emission
tomography
VOI  volume of interestdiffused to the whole LV (2–4). tEchocardiography. Comprehensive 2-dimensional and
Doppler echocardiographic studies were performed in each
patient using commercially available instruments. LV hy-
pertrophy was assessed by 2-dimensional echocardiography,
and the site and extent of maximal wall thickness were
identified (12). Peak instantaneous LV outflow gradient,
due to mitral valve systolic anterior motion and mitral-septal
contact, was estimated with continuous wave Doppler under
basal conditions (12).
Mutational analysis. Patients were screened for mutations
in the protein-coding exons and splice sites of 8 myofilament
genes, including myosin-binding protein C (MYBPC3), thick
filament proteins (beta-myosin heavy chain [MYH7] and the
regulatory and essential light chains), and thin filament
proteins (troponin T, troponin I, alpha-tropomyosin, and
alpha-actin). Direct DNA sequencing was accomplished
with the ABI-Prism 3730 (Applied Biosystems, Foster
City, California), as previously described (10). Every variant
identified was confirmed by direct sequencing and, when-
ever possible, by restriction enzyme digestion (10). Novel
mutations were considered as potentially disease causing
only if they were absent in at least 300 unrelated chromo-
somes from adult, ethnicity-matched healthy controls and
produced an amino acid change in a highly conserved
residue among species and isoforms (13). The Alamut
software version 1.5e (Interactive Biosoftware, Rouen,
France) was used for interpretation and reporting of unclas-
sified variants.
All patients with HCM with a negative sarcomere gene
test in the present study were screened for Fabry disease. In
men, leukocyte alfa-galactosidase (alfa-GLA) activity was
assessed, followed by genetic testing for alfa-GLA muta-
tions by automatic gene sequencing when positive; women
were assessed directly by genetic screening for alfa-GLA
gene mutations (1). None of the patients included in this
study proved affected.
Positron emission tomography. All PET scans were per-
formed in the nuclear medicine laboratory of the Depart-
ment of Clinical Physiopathology, Careggi University Hos-
pital in Florence, Italy, between September 2003 and
December 2008, after an appropriate period of pharmaco-
logical wash-out for patients receiving pharmacological
treatment, with the exception of amiodarone (14,15). Pa-
tients were positioned on the couch of the PET scanner
(General Electric Advance PET, Milwaukee, Wisconsin),
and a 5-min transmission scan was recorded for subsequent
attenuation correction of emission data. Then near-maximal
hyperemia was induced by intravenous administration of
dipyridamole (0.56 mg per kg of body weight over 4 min)
(15). Three minutes following the end of dipyridamole
infusion, a bolus of 370 MBq of 13N-ammonia diluted in 10
l of saline was injected intravenously over a period of 15 to
0 s and followed by a 10-ml saline flush at a rate of 2 ml/s.
dynamic scan with 15 frames of increasing duration was
cquired for 4 min, followed by a prolonged static acquisi-
ion of 15 min. Data were analyzed with an operator
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(16). Briefly, anatomic images were reconstructed using the
static acquisition and reoriented according to the heart axis.
After reconstruction, the dynamic images were reoriented as
well. On the short-axis slices, regions of interest were manually
drawn, including: 1) the right ventricular cavity; 2) the LV
cavity; and 3) the LV wall from the apex through the base
(identified by the appearance of the membranous septum). The
regions of interest were edited by the standard PMOD volume
of interest (VOI) tool to derive the related VOIs. The 3 VOIs
were then copied on all 13N-ammonia dynamic images to
extract the corresponding time-activity curves. The arterial
input function was obtained from the right and left ventricular
cavity time-activity curves. The myocardial uptake was derived
General Features of the 61 Study Patients WithTable 1 General Features of the 61 Study P
Overa
(N  6
Male 44 (72
Age at enrollment, yrs 38 1
Age at diagnosis, yrs 35 1
Family history of HCM 25 (41
Family history of juvenile sudden death 9 (15
NYHA functional class at enrollment 1.5 0
I 37 (61
II 21 (34
III 3 (5)
Syncope 16 (26
Atrial fibrillation 13 (21
Paroxysmal 8 (13
Persistent/permanent 5 (8)
Implantable cardioverter-defibrillator 16 (26
Medical treatment 49 (80
Beta-blockers 41 (67
Verapamil 6 (10
Amiodarone 7 (12
ACE inhibitors 5 (8)
Left atrium, mm 40 7
Maximal LV wall thickness, mm 25 6
Site of maximum LV wall thickness
Septum 58 (95
Other 3 (5)
LV end-diastolic diameter, mm 43 5
LV end-systolic diameter, mm 24 6
LV ejection fraction, % 71 9
With LVOT obstruction at rest (30 mm Hg)
Mitral regurgitation (1 to 4) 1.4 0
Diastolic pattern
Normal 26 (43
Delayed relaxation 18 (29
Pseudonormal 8 (13
Restrictive 9 (15
Presence of cardiac MRI-LGE* 30/35 (8
Cardiac MRI-LGE mass, % of whole LV* 6 9
Values are n (%) or mean SD unless otherwise indicated. *Of 35 pati
in the genotype-positive and 12 in the genotype-negative groups).
ACE angiotensin-converting enzyme; HCM hypertrophic cardiom
left ventricular outflow tract; NYHA  New York Heart Association.from the LV wall VOI. Myocardial perfusion was calculatedfrom the dynamic data by fitting the arterial input function and
tissue time-activity curves to a 2-tissue–compartment model
for 13N-ammonia developed by Hutchins et al. (17). Myocar-
ial blood flow (MBF) following dipyridamole infusion for the
ntire LV (Dip-MBF) was obtained by volume-weighted
veraging to the segment territories apex, septum, anterior,
ateral, and inferior. All images studies were analyzed by 1
xpert observer (R.S.) and blinded to patients’ genetic, clinical,
nd echocardiographic data.
ardiac MRI. Cardiac MRI was performed in 35 of the
1 study patients; the remaining 26 were excluded
ecause of contraindications to cardiac MRI, such as an
mplantable cardioverter-defibrillator (n  16), metallic
lips (n  3), or claustrophobia (n  2), or because they
ts With HCM
Genotype Positive
(n  42)
Genotype Negative
(n  19) p Value
29 (69) 15 (79) 0.42
39 14 35 15 0.34
34 13 31 14 0.41
17 (40) 8 (42) 0.90
5 (12) 4 (21) 0.44
1.5 0.6 1.4 0.4 0.32
26 (62) 11 (58)
13 (31) 8 (42) 0.58
3 (7) 0
11 (26) 5 (26) 0.99
11 (26) 2 (10) 0.44
7 (17) 1 (5) 0.38
4 (9) 1 (5) 0.42
13 (31) 3 (16) 0.34
35 (83) 14 (73) 0.31
29 (69) 12 (63) 0.58
5 (12) 1 (5) 0.27
5 (12) 2 (10) 0.78
4 (10) 1 (5) 0.36
40 7 39 9 0.49
25 5 26 8 0.55
40 (95) 18 (95) 0.9
2 (5) 1 (5)
44 5 41 6 0.13
25 6 23 5 0.14
70 9 72 8 0.89
0.67
1.4 0.9 1.3 0.6 0.66
16 (38) 10 (53)
15 (36) 3 (16) 0.25
4 (9) 4 (21)
7 (17) 2 (10)
22/23 (96) 8/12 (67) 0.038
16 15 17 10 0.83
whom cardiac magnetic resonance imaging (MRI) was performed (23
y; LGE late gadolinium enhancement; LV left ventricular; LVOTHCMatien
ll
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ents onrefused the test (n  5). Scans were performed using a
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Microvascular Dysfunction and Genotype in HCM August 16, 2011:839–48Individual Patient Features, Dip-MBF, and Mutational Screening ResultsTable 2 Individual Patient Features, Dip-MBF, and Mutational Screening Results
Patient # Age, yrs Sex
Maximal LV Wall
Thickness, mm
Dip-MBF,
ml/min/g Gene cNomen pNomen
Previously Described,
Company or Author
(Year) (Ref. #)
Genotype positive
1 15 F 23 1.6 MYH7 c.1358GA p.Arg453His Yu et al. (2005) (19)
2 17 M 32 1.3 MYH7 c.2573GC p.Arg858Pro No
3 20 F 24 2.4 MYBPC3 c.2157_2158del p.Cys719X No
4 21 F 28 1.5 MYL2 c.173GA p.Arg58Gln Flavigny et al. (1998) (20)
5 22 M 20 1.3 MYBPC3 c.772GA p.Glu258Lys Niimura et al. (1998) (21)
6 23 M 27 1.7 MYH7 c.1816GA p.Val606Met Watkins et al. (1992) (22)
7 23 M 39 1.3 MYBPC3 c.1020CG p.Tyr340X No
8 23 M 23 1.2 MYBPC3 c.2429GT p.Arg810Leu No
9 25 F 29 2.6 TNNT2 c.275GA p.Arg92Gln Thierfelder et al. (1994) (23)
10* 25 F 36 1.9 MYBPC3 c.3192dup p.Lys1065GlnfsX12 CardioGenomics
MYBPC3 c.1112CG p.Pro371Arg No
MYH7 c.2606GA p.Arg869His Van Driest et al. (2004) (24)
11 26 M 33 3.2 MYL2 c.173GA p.Arg58Gln Flavigny et al. (1998) (20)
12 26 F 27 1.3 TNNI3 c.257_258del p.Ala86GlyfsX23 No
MYBPC3 c.772GA p.Glu258Lys Niimura et al. (1998) (21)
MYH7 c.2606GA p.Arg869His Van Driest et al. (2004) (24)
13 27 M 15 3.1 MYBPC3 c.1591GC p.Gly531Arg CardioGenomics
14 30 M 22 1.7 MYH7 c.2893GA p.Glu965Lys No
15 33 M 17 1.1 MYBPC3 c.495GC p.Glu165Asp No
MYH7 c.2167CT p.Arg723Cys Watkins et al. (1992) (22)
MYH7 c.4363GT p.Glu1455X No
16 35 M 27 1.5 MYBPC3 c.772GA p.Glu258Lys Niimura et al. (1998) (21)
17 37 M 31 1.6 MYBPC3 c.2870CG p.Thr957Ser No
18 37 M 30 1.3 MYBPC3 c.1624GC p.Glu542Gln Carrier et al. (1997) (25)
19 37 M 26 2.8 MYBPC3 c.772GA p.Glu258Lys Niimura et al. (1998) (21)
20 38 M 27 1.5 MYBPC3 c.3192dup p.Lys1065GlnfsX12 CardioGenomics
21 39 M 23 1.3 MYH7 c.1063GA p.Ala355Thr Richard et al. (2003) (31)
22 40 F 19 1.5 TNNT2 c.487_489del p.Glu163del Watkins et al. (1995) (22)
23 41 M 25 1.4 MYBPC3 c.772GA p.Glu258Lys Niimura et al. (1998) (21)
MYBPC3 c.2728CA p.Pro910Thr No
24 42 M 25 1.7 MYBPC3 c.772GA p.Glu258Lys Niimura et al. (1998) (21)
25 42 M 26 1.1 MYBPC3 c.818GA p.Arg273His No
26* 42 M 19 1.2 MYBPC3 c.772GA p.Glu258Lys Niimura et al. (1998) (21)
MYBPC3 c.1321GA p.Glu441Lys No
27 43 F 22 1.5 MYH7 c.2594AG p.Lys865Arg No
28 43 M 19 2.2 MYBPC3 c.772GA p.Glu258Lys Niimura et al. (1998) (21)
29 43 M 22 0.6 MYBPC3 c.772GA p.Glu258Lys Niimura et al. (1998) (21)
30 45 M 27 1.7 MYH7 c.1987CT p.Arg663Cys Van Driest et al. (2004) (24)
31 47 M 18 2.1 MYBPC3 c.2258dup p.Lys754GlufsX79 CardioGenomics
32 47 F 20 2.2 MYBPC3 c.636CG p.Ser212Arg No
33 49 M 30 1.9 MYH7 c.1988GA p.Arg663His Gruver et al. (1999) (26)
34 51 M 20 2.1 MYBPC3 c.1828GC p.Asp610His No
35 53 F 21 3.8 MYBPC3 c.2077GT p.Ala693Ser No
MYBPC3 c.2356GT p.Asp786Tyr No
MYBPC3 c.772GA p.Glu258Lys Niimura et al. (1998) (21)
36 54 M 18 0.8 MYH7 c.2606GA p.Arg869His Van Driest et al. (2004) (24)
37 56 F 21 1.5 TPM1 c.842TC p.Met281Thr No
38 59 M 23 1.5 MYH7 c.2606GA p.Arg869His Van Driest et al. (2004) (24)
39 62 M 16 1.5 MYH7 c.2606GA p.Arg869His Van Driest et al. (2004) (24)
40 63 F 20 2.0 MYBPC3 c.1020CG p.Tyr340X No
41 63 M 30 0.7 MYBPC3 c.772GA p.Glu258Lys Niimura et al. (1998) (21)
42 63 M 30 1.2 MYBPC3 c.2905CT p.Gln969X Yu et al. (1998) (27)Continued on the next page
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August 16, 2011:839–48 Microvascular Dysfunction and Genotype in HCMPhilips ACS-NT 1.5-T Gyroscan-Intera (Best, the
Netherlands) using steady-state, free-precession breath-
hold cines in sequential 10-mm short-axis slices (no gap)
from the atrioventricular ring to the LV apex. LV
end-diastolic and end-systolic volumes, LV mass, and LV
wall thickness were calculated with commercially avail-
able workstations (Easy Vision 5.0 and View Forum,
Philips Medical Systems). LGE images were acquired 10
to 15 min after intravenous administration of 0.2
mmol/kg gadolinium– diethylene triamine pentaacetic
acid (Magnevist, Schering, Berlin, Germany) with
breath-held segmented inversion-recovery sequence, acquired
in the same orientations as the cine images (18). An inversion
time scout was used initially to find the optimal inversion time
to null normal myocardium (typically 240 to 300 ms). To
ascertain the presence of LGE, all tomographic short-axis
LV slices from base to apex were inspected visually to
identify an area of completely nulled myocardium (18).
Mean signal intensity (and SD) of normal myocardium was
calculated, and a threshold of 2 SD exceeding the mean
was used to define areas of LGE.
Statistical analysis. Unpaired Student t test or 1-way
nalysis of variance (ANOVA) was used for the comparison
f normally distributed data. Chi-square or Fisher exact test
ere used to compare noncontinuous variables expressed as
roportions. Relationships between independent variables
ere assessed with Spearman bivariate correlation analysis.
azard ratios (HRs) and 95% confidence intervals (CIs)
ContinuedTable 2 Continued
Patient # Age, yrs Sex
Maximal LV Wall
Thickness, mm
Dip-MBF,
ml/min/g G
Genotype negative
1 15 M 27 4.0 No
2 16 M 38 3.9 No
3 17 F 25 5.6 No
4 18 M 20 1.4 No
5 21 F 31 1.7 No
6 22 M 43 2.7 No
7 26 M 20 3.3 No
8 31 M 20 1.9 No
9 32 M 32 2.1 No
10 35 M 24 1.4 No
11 35 F 27 2.5 No
12 37 M 18 1.5 No
13 38 M 18 1.1 No
14 50 F 23 2.1 No
15 51 M 21 1.6 No
16 51 M 28 1.3 No
17 52 M 30 2.3 No
18 55 M 16 1.5 No
19 64 F 18 3.9 No
*Patients with complex genotypes.
Dip-MBF  dipyridamole myocardial blood flow; MYBPC3  myosin-binding protein C; MYH7 
; TNNT2  troponin T; TPMI  alpha-tropomyosin; other abbreviations as in Table 1.ere calculated using univariate logistic regression analysis. (ll calculations were performed using SPSS software ver-
ion 12.0 (SPSS Inc., Chicago, Illinois).
esults
eneral patient features. Of the 61 study patients, most
95%) were in NYHA functional class I or II (Table 1).
verage LV wall thickness was 25  6 mm (range 15 to 45
m); among the 35 patients with cardiac MRI, LV mass
ndex ranged from 66 to 369 g/m2 (average 128 68 g/m2).
Eight patients (13%) had dynamic LV outflow obstruction
under resting conditions, 13 (21%) had a history of parox-
ysmal or permanent atrial fibrillation, and 16 patients (26%)
had received an implantable cardioverter-defibrillator for
primary (n  13) or secondary (n  3) prophylaxis of
udden cardiac death. None of the study patients had
vidence of overt systolic dysfunction (i.e., LV ejection
raction 50%) at the time of the PET scan, although 4
atients had an LV ejection fraction in the low to normal
ange for HCM (55% to 65%).
utational analysis. Patients underwent comprehensive
utational analysis for 8 HCM-associated sarcomere genes.
verall, 53 mutations were identified in 42 of the 61 study
atients (69%). Of these 42 genotype-positive patients, 36
ad single, 2 had double, and 4 had triple mutations (Table 2)
19–27). Specifically, 20 patients had mutations in MYBPC3
48%), 11 in MYH7 (26%), and 11 (26%) had mutations in
he remaining 6 genes or had complex genotypes. Of the 53
utations, 33 (62%) had been previously described and 20
cNomen pNomen
Previously Described,
Author (Year) (Ref. #)
N/A N/A N/A
N/A N/A N/A
N/A N/A N/A
N/A N/A N/A
N/A N/A N/A
N/A N/A N/A
N/A N/A N/A
N/A N/A N/A
N/A N/A N/A
N/A N/A N/A
N/A N/A N/A
N/A N/A N/A
N/A N/A N/A
N/A N/A N/A
N/A N/A N/A
N/A N/A N/A
N/A N/A N/A
N/A N/A N/A
N/A N/A N/A
yosin heavy chain; MYL2  myosin essential light chain; N/A  not applicable; TNNI3  troponinene
ne
ne
ne
ne
ne
ne
ne
ne
ne
ne
ne
ne
ne
ne
ne
ne
ne
ne
ne38%) were novel; among the latter, most (n  13 [65%])
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Microvascular Dysfunction and Genotype in HCM August 16, 2011:839–48had evidence of cosegregation within the family. In each
case, the mutation affected a highly conserved residue, and
the genetic defect was considered pathogenic with high
likelihood by the Alamut software. Genotype-positive and
genotype-negative patients were similar with regard to age
at enrollment, sex, maximum LV thickness, left atrial size,
prevalence of symptoms, ejection fraction, and mitral regur-
gitation under resting conditions (Table 1). Age at first
diagnosis of HCM was also similar (34  13 years vs. 31 
14 years, respectively; p  0.41). Finally, the 2 subsets had
comparable prevalence of family history for HCM, based on
direct questioning and review of available clinical documen-
tation (Table 1). Direct evaluation of first-degree relatives
was not performed.
PET study results. Blood pressure measured at the time
of PET scan was comparable in the genotype-positive
and genotype-negative patient subsets, both at baseline
(systolic 122  15 mm Hg vs. 116  13 mm Hg, p 
0.14; diastolic 74  8 mm Hg vs. 72  9 mm Hg, p 
0.39, respectively) and following dipyridamole infusion
(systolic 120  14 mm Hg vs. 113  15 mm Hg, p 
0.09; diastolic 71  8 mm Hg vs. 70  10 mm Hg, p 
0.67, respectively). Mean Dip-MBF for the whole LV in the
61 study patients was 1.9  0.9 ml/min/g, ranging from 0.6
to 5.6 ml/min/g. Twenty-one patients were in the lowest
tertile of Dip-MBF (1.5 ml/min/g), indicative of severe
CMD, and 20 patients each were in the intermediate and
highest tertiles (1.5 to 2.0 ml/min/g and 2.0 ml/min/g,
respectively). Dip-MBF showed a weak inverse relation to
Figure 1 Comparison of Dip-MBF Between Genotype-Positive
and -Negative Patients With HCM
Mean and individual values are shown for each group. Dip-MBF  myocardial
blood flow following dipyridamole; HCM  hypertrophic cardiomyopathy;
MYBPC3  myosin-binding protein C; MYH7  beta-myosin heavy chain.age at enrollment (correlation coefficient 0.28, p  0.027) gbut had no relationship with sex, NYHA functional class,
maximum LV thickness, or presence of LV outflow obstruc-
tion (p  0.8 for all). There was no significant difference in
flow based on septal morphology (Dip-MBF 1.7  0.7
ml/min/g, 1.9  0.8 ml/min/g, and 2.4  1.7 ml/min/g in
patients with reverse curvature, sigmoid, and apical sub-
types, respectively, p  0.11). Furthermore, we observed no
difference in Dip-MBF between patients in chronic treat-
ment with beta-blockers or verapamil (1.9  0.8 ml/min/g
s. 2.1  1.1 ml/min/g, respectively, p  0.32).
elevance of mutational status to Dip-MBF. Despite
imilar baseline features, Dip-MBF in genotype-positive
atients averaged only 1.7 ml/min/g (range 0.6 to 3.8
l/min/g) and was significantly lower than that in
enotype-negative patients (2.4 ml/min/g; range 1.1 to 5.6
l/min/g; p  0.019) (Fig. 1). Only 24% of genotype-
ositive patients with HCM were in the highest tertile of
ip-MBF (2.0 ml/min/g), compared with 53% of pa-
ients with a negative genetic test; conversely, 40% of
enotype-positive patients were in the lowest tertile (Dip-
BF 1.5 ml/min/g), compared with 21% of genotype
egative (overall p  0.07). Of note, among 5 patients in
he pediatric age range (18 years), the 2 with sarcomere
yofilament mutations (i.e., MYH7-Arg453His and
YH7-Arg858Pro) had blunted Dip-MBF values of 1.3
nd 1.6 ml/min/g, whereas the 3 genotype-negative
atients had normal values ranging from 3.9 to 5.6
l/min/g (Fig. 2).
Overall, a Dip-MBF 1.5 ml/min/g had an 81% positive
redictive value with regard to genotype-positive status. Con-
ersely, a Dip-MBF in the highest tertile (2.0 ml/min/g) was
ssociated with a 72% reduction in likelihood of genotype-
ositive status, compared with values 2.0 ml/min/g (HR:
.28, 95% CI: 0.09 to 0.88, p  0.03). Stepwise logistic
egression analysis showed Dip-MBF to be the only indepen-
ent predictor of genotype-positive status (Table 3): values
1.5 ml/min/g implied a 3.5-fold increase in likelihood of
arrying 1 or more myofilament gene mutations (HR: 3.52,
5% CI: 1.05 to 11.7, p  0.04).
Among genotype-positive patients, there was no differ-
nce in average Dip-MBF with respect to the 2 major genes
1.7  0.6 ml/min/g for MYBPC3 vs. 1.5  0.3 ml/min/g
or MHY7, respectively; p  0.23). However, patients with
YBPC3 mutations showed a broad spectrum of flow values
range 0.6 to 3.1 ml/min/g), whereas those with MYH7
utations a narrow range that was constantly below 2
l/min/g (range 0.8 to 1.9 ml/min/g) (Fig. 1).
ate gadolinium enhancement. Of the 35 patients with
ardiac MRI, 30 (86%) showed evidence of LGE, averaging 31
37 ml in volume or 6  9% of the whole LV (Table 1).
revalence of LGE was greater in the genotype-positive
ubgroup (22 of 23 [96%] compared with 8 of 12 [67%] in
he genotype-negative group; p  0.038). However, there
as no significant difference in LGE volume between the 2
roups (Table 1).
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Genetic status and microvascular dysfunction in HCM.
HCM is the most common genetic cardiac disease, charac-
terized by heterogeneous morphologic expression and clin-
ical course (1,3,9,11,12,18). Mutations in genes coding for
myofilament contractile proteins of the cardiac sarcomere
characterize the most common genetic subtype of HCM,
with a 30% to 65% prevalence in various cohort studies
(10,28–31). As novel genes associated with HCM are being
discovered, these only account for a small fraction of
individual cohorts (29,32). Therefore, a considerable pro-
portion of patients prove genotype negative even after the
most comprehensive mutational screening (19).
Recent evidence shows that patients in whom HCM is
associated with proven sarcomere myofilament mutations
have substantial prevalence of disease progression, LV
dysfunction, and likelihood of end-stage development
(10,33,34), which is not as common among genotype-
Figure 2 Genetic Status and Microvascular Function in 2 Adole
(A and B) Cardiac magnetic resonance short-axis and (C and D) 4-chamber views
negative genetic screening (right). Both patients have the typical HCM phenotype
obtained with positron emission tomography after dipyridamole infusion show seve
ml/min/g) but not in the (F) genotype-negative patient, in whom myocardial flow anegative patients (10). Such risk becomes particularlymarked in the presence of multiple mutations (35–37). On
the other hand, there is substantial evidence suggesting a
pivotal role of microvascular ischemia in determining LV
remodeling and replacement fibrosis—2 hallmarks of end-
stage HCM (2,11). Importantly, severe CMD is an impor-
tant predictor of adverse outcome because of heart failure–
related complications in these patients (3,4). Therefore, we
hypothesized that the more frequent occurrence of disease
progression and LV dysfunction observed in patients with
HCM with sarcomere myofilament mutations might be
related to more prevalent and severe impairment of the
coronary microcirculation (9).
The findings of the present investigation support this
hypothesis. In our 61 patients assessed by mutational
analysis for the most frequent HCM-causing genes, Dip-
MBF was more frequently and severely impaired in
genotype-positive individuals, compared with the genotype
negative, despite similar baseline features including age,
ts With HCM
5-year-old girl with HCM-causing MHY7 mutation (left) and 16-year-old boy with
evere asymmetric hypertrophy localized at the ventricular septum. Polar maps
rovascular dysfunction in the (E) genotype-positive (mean Dip-MBF 1.6
to be preserved (mean Dip-MBF 3.9 ml/min/g). Abbreviations as in Figure 1.scen
in a 1
with s
re mic
ppearssymptoms, degree of hypertrophy, and functional LV char-
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prevalence of outflow obstruction. Dip-MBF averaged only
1.7 ml/min/g in genotype-positive patients with HCM,
compared with 2.4 ml/min/g in genotype negative.
Genotype-positive patients were one-half as likely to be in
the highest tertile of flow for the whole group (Dip-MBF
2.0 ml/min/g), compared with genotype negative, but
twice as likely to be in the lowest tertile (Dip-MBF 1.5
ml/min/g), reflecting profound microvascular dysfunction.
Specifically, all patients with MHY7 mutations showed a
blunted response to dipyridamole, with flow values consis-
tently below the 2 ml/min/g threshold. In addition, we
observed a higher prevalence of LGE among genotype-
positive patients in our cohort, suggesting that the milieu
associated with myofilament mutations may be more sus-
ceptible to replacement fibrosis and LV remodeling (6,8,38).
Two potentially important concepts can be derived from
our observations. The first is that severe impairment of
microvascular function is not an obligate consequence of the
HCM phenotype; in genotype-negative patients, a broad
range of Dip-MBF values was observed, including patients
with relatively preserved flow despite massive hypertrophy,
as shown in Figure 2. The second is that genotype-positive
patients with HCM exhibited a more stereotypical response
to dipyridamole, which is, with few exceptions, severely
impaired. This supports the idea that the specific genetic
defect causing HCM may represent a major determinant of
microvascular remodeling, as originally hypothesized. In a
broader prospective, our findings suggested that arteriolar
remodeling is regulated by selective activation of molecular
pathways that are largely independent of hypertrophy itself,
consistent with the great heterogeneity of microvascular
involvement observed in patients with secondary LV hyper-
trophy (7). For example, microvascular remodeling is an
established feature of hypertensive heart disease and appears
to be finely regulated at the molecular level, whereas aortic
Logistic Regression Analysis AssessingPredictors of Gen type-Po tive StatusTable 3 Logistic Regression Analysis AssessingPredictors of Genotype-Positive Status
p Value
Hazard Ratio
(95% Confidence
Interval)
Dip-MBF (per ml/min/g increase) 0.007 0.34 (0.15–0.74)*
Left atrial diameter (per mm increase) 0.82
Age 0.72
Female sex 0.24
Family history of HCM 0.77
Family history of sudden cardiac death 0.52
NYHA functional class 0.13
Atrial fibrillation 0.77
LV outflow obstruction 0.96
Maximum LV thickness 0.72
End-diastolic LV diameter (per mm increase) 0.58
*Preserved Dip-MBF is inversely associated with the likelihood of carrying a sarcomere myofila-
ment gene mutation.
Abbreviations as in Tables 1 and 2.stenosis seems to cause significantly milder degrees ofmicrovascular remodeling, despite similar or greater magni-
tude of LV hypertrophy (7).
Of note, we observed an inverse relationship between age
at enrollment and Dip-MBF. However, such a relationship
was very weak (correlation coefficient 0.28, p  0.027),
suggesting that duration of disease is not a major determi-
nant of microvascular dysfunction. Such a concept is con-
sistent with previous work by our group (4,15), demonstrat-
ing that severe CMD leading to LV remodeling and
end-stage disease may occur at any age in patients with
HCM.
Clinical implications. From a clinical perspective, sarco-
mere myofilament mutations seem to confer a distinctly
increased risk of disease progression and heart failure–
related complications in patients with HCM, mediated by
severe microvascular dysfunction, myocardial ischemia, fi-
brosis, and remodeling (2). Patients with complex geno-
types, harboring double or triple genetic defects, by virtue of
their severe phenotype and clinical course, represent extreme
paradigms supporting an association between genetic status
and outcome (35–37). Consequently, our findings empha-
size the clinical relevance of systematic genetic screening in
HCM populations, potentially guiding surveillance strate-
gies and early medical intervention with antiremodeling
therapies aimed at preventing disease progression in predis-
posed individuals (2,19,29). Preliminary evidence suggests
the possibility of targeting CMD by specific pharmacolog-
ical interventions in patients with secondary LV hypertro-
phy (39,40), and this appears promising for patients with
HCM as well. However, our findings suggest that selection
of individuals with a homogeneous and well-defined genetic
background, particularly aimed at individuals with sarco-
mere myofilament mutations, is mandatory to obtain mean-
ingful and reproducible results (10).
Potential mechanisms. The link between sarcomere gene
mutations and CMD remains elusive (9). Patients with
HCM exhibit striking anatomic remodeling of the intra-
mural coronary arterioles, predominantly characterized by
smooth muscle hypertrophy in the tunica media leading to
lumen reduction and inability to properly vasodilate in
response to physiological or pharmacological stimuli (7).
However, none of the cells involved in microvascular re-
modeling are known to express the sarcomere proteins that
are mutated in HCM (9). Therefore, it is difficult to
postulate a direct effect of HCM-causing mutations on
small vessels. One possibility is that microvascular remod-
eling might represent secondary, maladaptive changes trig-
gered by abnormal LV wall stress or other hemodynamic
abnormalities, similar to those found in arterial hyperten-
sion (7). Such a hypothesis, however, fails to explain CMD
observed in patients with very mild hypertrophy, including
young children, with normal LV function and no evidence
of outflow obstruction (2,9).
An alternative, although not mutually exclusive, explana-
tion is represented by the possibility of a developmental
origin of microvascular abnormalities in patients with HCM
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cells that colonize the embryonic heart when the cardiomy-
ocytes have already begun to contract (41). The exposure of
coronary precursors to abnormal mechanical stimuli, result-
ing from myofilament mutation effect on sarcomere func-
tion, may be capable of influencing their development
(9,41,42). Of note, the same mechanism may explain other
phenotypic expressions of HCM involving systems of pro-
epicardial origin, such as mitral valve abnormalities and
irregular development of the fibrous heart skeleton, produc-
ing disarray (9,42). Further studies are needed to test such
hypotheses. Intriguingly, however, the role of developmen-
tal influences on the phenotype of cardiomyopathy patients
is beginning to surface for other conditions such as LV
noncompaction and arrhythmogenic right ventricular car-
diomyopathy (41,43).
Study limitations. We are aware that to consider patients
with none of the known HCM-causing mutations as a
single group represents an unavoidable oversimplification of
the present study, calling for further research in this area.
Genotype-negative HCM represents a composite entity,
probably comprising a multitude of rare, heterogeneous, and
yet-to-be identified HCM-susceptibility genes. To date,
more than 20 different candidate genes have been identified,
including titin, muscle LIM protein, telethonin, myozenin,
vinculin, and actinin (19). Nevertheless, the prevalence of
mutations in these newly discovered genes is very low (5%
combined); therefore, even a very extensive screening would
not have altered our study results significantly. It is hoped
that the yield of genetic testing in genotype-negative HCM
will radically improve in the near future with the advent of
next-generation sequencing techniques, allowing a whole-
genome approach (28).
Automatic DNA sequencing, used in the present study
for mutational analysis and representing the standard in
HCM genetic testing, is not capable of detecting large
insertions/deletions. Therefore, we cannot exclude that a
subset of genotype-negative patients may carry such defects
within sarcomere myofilament genes that were not recog-
nized. Nevertheless, in the only study specifically addressing
this issue, large deletions and duplications in MYBPC3 and
troponin T appeared to be exceedingly rare (44).
Conclusions
Sarcomere myofilament mutations are associated with se-
vere blunting of microvascular function in patients with
HCM, to a degree that is not observed in genotype-negative
individuals. These findings suggest that sarcomere gene
mutations might be directly involved in the generation of
adverse remodeling of the microcirculation, ischemia, and
replacement fibrosis in HCM, accounting for the greater
prevalence of ventricular dysfunction and cardiac failure
compared with genotype-negative disease.Reprint requests and correspondence: Dr. Iacopo Olivotto,
Centro di Riferimento per le Cardiomiopatie, Cardiologia San
Luca, Azienda Ospedaliera Universitaria Careggi, Viale Pieraccini
19, 50134 Firenze, Italy. E-mail: olivottoi@aou-careggi.toscana.it.
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